Methanex Corp.
CITIGROUP FUNDING
Crown Holdings Inc.

Technology Research Corp. (TRCI)

Market Cap: 22.08M
Trailing PE: 7.32
Forward PE: N/A
Price to Sales Ratio: 0.62
Price to Book Ratio: 0.91
Fiscal Year End: 31-Mar
Most Recent Quarter: 30-Sep-09
Profit Margin: 8.76%
Return on Equity: 22.08M
Revenue: 0.31
Revenue per Share: 5.963
Quarterly Revenue Growth: 3.50%
Gross Profit: 11.47M
EBITDA: 5.16M
Net Income: 3.03M
Diluted EPS: 0.512
Quarterly Earnings Growth: 29.70%
Total Cash: 11.07M
Total Cash per Share: 1.879
Total Debt: 0
Total Debt to Equity Ratio: N/A
Current Ratio: 8.053
Book Value Per Share: 4.061
Operating Cash Flow: 5.80M
Levered Free Cash Flow: 4.53M
52 Week Change: 115.70%
S&P 500 52 Week Change:
52 Week High: 4.24
52 Week Low: 1.32
50 Day Moving Average: 3.7435
200 Day Moving Average: 3.2733
Average Volume (3 months): 22,945.3
Average Volume (10 day): 8,966.67
Shares Outstanding: 5.89M
Float: 4.40M
Held by Insiders: 13.67%
Held by Institutions: 20.70%
Shares Short: 391
Short Ratio: 0
Short % of Float:
N/A:
:
Shares Short: 391
Forward Annual Dividend Rate: 0.08
Forward Annual Dividend Yield: 2.10%
Ex-Dividend Date: 29-Dec-10
Key Stats:
Daily Price Action:
Date Open High Low Close Volume
2010-03-254.644.679000
2010-03-244.534.6014600
2010-03-234.404.6012200
2010-03-224.414.5510900
2010-03-194.584.508400
2010-03-184.574.564100
2010-03-174.524.5540800
2010-03-164.494.5018900
2010-03-154.524.433500
2010-03-124.414.5325300
2010-03-114.444.4520500
2010-03-104.534.5221000
2010-03-094.424.5112200
2010-03-084.524.5032700
2010-03-054.484.5354900
2010-03-044.264.4429900
2010-03-033.924.25102900
2010-03-023.863.8521400
2010-03-013.733.7714000
2010-02-263.633.7319500
2010-02-253.623.6311800
2010-02-243.513.5425800
2010-02-233.493.4934000
2010-02-223.443.4522500
2010-02-193.613.4932200
2010-02-183.423.4411600
2010-02-173.493.4314300
2010-02-163.543.488200
2010-02-123.503.5419800
2010-02-113.353.501500
2010-02-103.413.4811600
2010-02-093.433.394700
Company Profile:

Other Companies:   iShares MSCI Hong Kong Index | Nucryst Pharmaceuticals Corporation | Ultra S&P500 ProShares